TY - JOUR
T1 - p53-Based cyclotherapy
T2 - exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy
AU - Rao, B.
AU - Lain, S.
AU - Thompson, A. M.
PY - 2013/12/10
Y1 - 2013/12/10
N2 - Side effects of chemotherapy are a major impediment in the treatment of cancer. Cyclotherapy is an emerging therapeutic strategy for protecting normal cells from the side effects of chemotherapy. Low, non-genotoxic doses of known p53 activators can be used to induce p53-dependent cell cycle arrest in normal cells bearing wild-type p53. This cytostatic effect of p53 can protect normal cells from the toxicity of S- or M-phase poisons. Here, we have reviewed existing cyclotherapy regimens using two well-known p53 activators, nutlin-3 and actinomycin D. We have highlighted an exemplar clinical perspective for cyclotherapy in breast cancer. The recent development of novel stapled peptides as activators of p53 without the corresponding cytotoxicity holds great promise for cyclotherapy to enhance the therapeutic window of existing chemotherapy drugs.British Journal of Cancer advance online publication, 14 November 2013; doi:10.1038/bjc.2013.702 www.bjcancer.com.
AB - Side effects of chemotherapy are a major impediment in the treatment of cancer. Cyclotherapy is an emerging therapeutic strategy for protecting normal cells from the side effects of chemotherapy. Low, non-genotoxic doses of known p53 activators can be used to induce p53-dependent cell cycle arrest in normal cells bearing wild-type p53. This cytostatic effect of p53 can protect normal cells from the toxicity of S- or M-phase poisons. Here, we have reviewed existing cyclotherapy regimens using two well-known p53 activators, nutlin-3 and actinomycin D. We have highlighted an exemplar clinical perspective for cyclotherapy in breast cancer. The recent development of novel stapled peptides as activators of p53 without the corresponding cytotoxicity holds great promise for cyclotherapy to enhance the therapeutic window of existing chemotherapy drugs.British Journal of Cancer advance online publication, 14 November 2013; doi:10.1038/bjc.2013.702 www.bjcancer.com.
U2 - 10.1038/bjc.2013.702
DO - 10.1038/bjc.2013.702
M3 - Article
C2 - 24231949
SN - 0007-0920
VL - 109
SP - 2954
EP - 2958
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 12
ER -
